arrow
C

Concetta Conticello

irccs istituto oncologico veneto (iov)
H指数:30
被引数:4,796

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy

多发性骨髓瘤患者在来那度胺维持治疗后进展的挽救治疗模式:欧洲骨髓瘤网络(EMN)意大利的真实世界研究

2026-09-050
OAAI
FcγRIIIA Genotype in Plasma Cell Dyscrasias Is Associated with Clinical Progression, Bone Disease Extension and Immune Dysfunction

FcγRIIIA基因型在浆细胞恶性疾病中与临床进展、骨病变扩展和免疫功能紊乱相关

Cancers
IF4.4
2026-04-030
OAAI
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy

更正:连续或固定剂量卡非佐米、来那度胺和地塞米松(KRD)用于复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络(EMN)意大利多中心回顾性真实世界调查的长期随访结果

2025-11-130
OAAI
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy

连续或固定剂量卡非佐米、来那度胺和地塞米松 (KRd) 治疗复发/难治性多发性骨髓瘤:来自欧洲骨髓瘤网络 (EMN) 意大利 多中心、回顾性真实世界研究的长-term随访

2025-10-070
OA
Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients

来那度胺维持治疗在硼替佐米、沙利度胺和地塞米松(VTD)诱导治疗及自体干细胞移植后的应用:一项意大利真实世界研究,共纳入602例患者

2025-10-011
OAAI
Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study

伊沙佐米单抗、卡非佐米和地塞米松(IsaKd)在自体干细胞移植和来那度胺维持治疗后首次复发的多发性骨髓瘤患者中的有效性与安全性:来自多中心、真实世界AENEID研究的结果

2025-04-190
OA
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study

伊沙图昔单抗、泊马度胺和地塞米松 (IsaPd) 在达雷妥尤单抗难治性多发性骨髓瘤患者中的疗效和预后指标: 一项多中心真实世界研究

2025-02-030
OAAI
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients

daratumumab难治性多发性骨髓瘤的结局和预后指标: 埃洛妥珠单抗,波马利多明和地塞米松在247患者中的多中心真实世界研究

2025-02-011
PRE
Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis
2024-11-260
OAAI
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis

新诊断的轻链 (AL) 淀粉样变性患者的daratumumab组合的现实生活研究

2024-06-020
PRE
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials
2024-05-314
PRE
Daratumumab-based regimens for patients with multiple myeloma plus extramedullary plasmacytomas or paraskeletal plasmacytomas: initial follow-up of an Italian multicenter observational clinical experience

基于Daratumumab的多发性骨髓瘤加髓外浆细胞瘤或骨骼旁浆细胞瘤患者的方案: 意大利多中心观察性临床经验的初步随访

2024-05-280
PRE
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions

在血液学条件下,tixagevimab-cilgavimab与SARS-CoV-2突破性感染的疗效和安全性

CANCER
IF5.1
2023-09-019
PRE
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials
2023-07-1312
OAAI
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab

接种和预防tixagevimab/cilgavimab后,多发性骨髓瘤患者发生SARS-CoV-2感染的临床结果

2023-03-298
OAAI
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials

接受埃罗妥珠单抗或卡非佐米联合来那度胺和地塞米松作为挽救疗法的真实复发/难治性多发性骨髓瘤患者的生存风险评分: 临床试验以外的919例分析

2022-07-184
OAAI
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant
2022-07-116
OAAI
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials
2022-06-069
PRE
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials
2022-06-0111
OA
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
2022-01-2128
OAAI